- Home
- SDA vs CHRS Comparison
SDA vs CHRS Comparison
Compare SDA & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDA | CHRS |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.2M | 186.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | SDA | CHRS |
|---|---|---|
| Price | $2.05 | $1.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $4.75 | $4.02 |
| AVG Volume (30 Days) | 47.2K | ★ 1.2M |
| Earning Date | 12-18-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.34 |
| Revenue | ★ $467,272,000.00 | $277,728,000.00 |
| Revenue This Year | $10.86 | N/A |
| Revenue Next Year | $13.07 | $67.31 |
| P/E Ratio | ★ N/A | $1.27 |
| Revenue Growth | 9.69 | ★ 152.07 |
| 52 Week Low | $1.54 | $0.71 |
| 52 Week High | $10.61 | $1.89 |
Technical Indicators
Market Signals| Indicator | SDA | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 61.62 |
| Support Level | $2.02 | $1.35 |
| Resistance Level | $2.15 | $1.78 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 57.14 | 69.31 |
Price Performance
Historical ComparisonAbout SDA SunCar Technology Group Inc.
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.